Half dosing Mounjaro: what patients ask and what prescribers say

Step 1 — Understand what the KwikPen can and cannot do

The Mounjaro KwikPen is a pre-filled, single-use injection device. Each pen contains four weekly doses at a single fixed strength: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on which box you have. When you press the button, the pen delivers that full pre-set volume in one injection. There is no plunger to stop partway through and no dose selector to turn down before injecting.

This matters because the idea of "half dosing" usually assumes you can draw out less liquid or stop the mechanism early. With a KwikPen, neither is possible in a controlled, accurate way. The volume per dose is small, and any attempt to interrupt the injection mid-press would result in an unknown quantity being delivered, not a reliable half. The NHS medicines page for tirzepatide is clear that the pen should be used exactly as described in the Patient Information Leaflet, and the leaflet itself gives no instructions for partial doses because none are licensed.

If you are curious about how to use the pen correctly at each stage of treatment, the guide to using the 2.5 mg KwikPen covers the steps in detail.

Step 2, Recognise why the starter dose already serves the purpose people think halving would achieve

Most people who ask about halving their dose are trying to manage nausea, fatigue, or other gastrointestinal symptoms that can appear in the first few weeks of treatment or after a dose increase. That instinct is understandable. The good news is that the licensed schedule already builds in a mitigation for exactly this.

Treatment begins at 2.5 mg for the first four weeks. That starting strength exists to let the body adjust to the medicine's mechanism, it slows gastric emptying, which changes how quickly food moves through the stomach, and the body needs time to settle. The 2.5 mg pen's job is adjustment, not weight loss. Moving too quickly to a higher strength is where most side effects become difficult, and the prescriber-controlled titration pace is the built-in safety feature.

At 5 mg and above, dose increases are made no sooner than every four weeks, again giving the body a settling-in window. For a broader look at how the full dose ladder works, the 5 mg Mounjaro page explains what changes at that stage.

NICE's appraisal of tirzepatide (TA1026) recommends that if a patient cannot tolerate a dose increase, continuing at the last tolerated dose is appropriate before reviewing. That is the clinically supported response to intolerance: pause, not improvise.

Step 3, Talk to your prescriber before changing anything about how you take the pen

If your current dose feels too strong, the correct step is a conversation with a prescriber, not a self-managed adjustment. A prescriber can do things that are both safe and licensed: they can delay a scheduled dose increase, recommend a slower titration path, or review whether another aspect of your routine (eating habits, hydration, timing of the injection) might be contributing to how you feel.

At nume, every repeat order goes through a fresh clinical review by a GPhC-registered prescriber before anything is approved or dispatched. If you are finding a dose difficult, raising that during your review is exactly what the process is for. You can explore how that works on the Mounjaro treatment page.

For anyone asking specifically whether halving a dose is something that can be done, the short answer is: the pen is not built for it, the licence does not support it, and the better route is already inside the clinical pathway. More detail on that question, and the specific clicks involved in using the pen, is covered on the half-dose clicks guide.

What about switching doses between pens of different strengths?

A separate question that sometimes sits alongside this one is whether someone could use a lower-strength pen than prescribed, for example, staying on the 5 mg pen when 7.5 mg has been clinically recommended. This is a different scenario from physically splitting a single injection, but it raises the same principle: dose decisions are made by the prescriber based on your clinical picture, not by choosing a different box from the pharmacy.

There is no clinical evidence that using a lower-strength pen of your own choosing produces the same outcomes as the licensed titration schedule, and doing so without telling your prescriber means they are making decisions based on inaccurate information. The detailed guide on whether halving a dose is possible covers this scenario more fully, along with the question of what half-dose clicks means in practice.

If you are weighing up your options or want to understand the full treatment landscape before starting, the free consultation with our prescribers is the right place to begin.